Kynurenines and other novel therapeutic strategies in the treatment of dementia

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 6, 2013, Pages 386-397

  Majlath, Zsofia ^a   Tajti, Janos ^a   Vecsei, Laszlo ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Alzheimer's disease; dementia; kynurenine; neuroprotective agents

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 4 CHLOROKYNURENINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; HUNTINGTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENIC ACID; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; KYNURENINE AMINOTRANSFERASE; MEMANTINE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; QUINOLINIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL FEATURE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; ENZYME ACTIVITY; ENZYME DEGRADATION; FRONTOTEMPORAL DEMENTIA; HIV ASSOCIATED DEMENTIA; HUMAN; HUNTINGTON CHOREA; LIPID METABOLISM; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; NORMOTENSIVE HYDROCEPHALUS; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 84887852605     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285613494989     Document Type: Article

References (114)

1. Aisen P. (2002) The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol 1: 279–284.
2. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, 4th ed. Washington, DC: American Psychiatric Association
3. Bahn A. Ljubojevic M. Lorenz H. Schultz C. Ghebremedhin E. Ugele B. et al (2005) Murine renal organic anion transporters mOAT 1 and mOAT 3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol 289: C1075-C1084.
4. Baran H. Jellinger K. Deecke L. (1999) Kynurenine metabolism in Alzheimer's disease. J Neural Transm 106: 165–181.
5. Battie C. Verity M. (1981) Presence of kynurenine hydroxylase in developing rat brain. J Neurochem 36: 1308–1310.
6. Battistin L. Cagnin A. (2010) Vascular cognitive disorder. A biological and clinical overview. Neurochem Res 35: 1933–1938.
7. Beadle G. Mitchell H. Nyc J. (1947) Kynurenine as an intermediate in the formation of nicotinic acid from tryptophane by neurospora. Proc Natl Acad Sci U S A 33: 155–158.
8. Beal M. Matson W. Swartz K. Gamache P. Bird E. (1990) Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55: 1327–1339.
9. Birch P. Grossman C. Hayes A. (1988) Kynurenate and FG 9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur J Pharmacol 151: 313–315.
10. Burt T. Agan B. Marconi V. He W. Kulkarni H. Mold J. et al (2008) Apolipoprotein (apo) E 4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A 105: 8718–8723.
11. Campesan S. Green E. Breda C. Sathyasaikumar K. Muchowski P. Schwarcz R. et al (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 21: 961–966.
12. Chess A. Simoni M. Alling T. Bucci D. (2007) Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr Bull 33: 797–804.
13. Choi S. Aid S. Caracciolo L. Minami S. Niikura T. Matsuoka Y. et al (2013) Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem 124: 59–68.
14. Corder E. Saunders A. Strittmatter W. Schmechel D. Gaskell P. Small G. et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921–923.
15. Csillik A. Knyihar E. Okuno E. Krisztin-Peva B. Csillik B. Vécsei L. (2002) Effect of 3-nitropropionic acid on kynurenine aminotransferase in the rat brain. Exp Neurol 177: 233–241.
16. Darlington L. Mackay G. Forrest C. Stoy N. George C. Stone T. (2007) Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci 26: 2211–2221.
17. Darvesh S. Leach L. Black S. Kaplan E. Freedman M. (2005) The behavioural neurology assessment. Can J Neurol Sci 32: 167–177.
18. de Carvalho L. Bochet P. Rossier J. (1996) The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR 2 receptor subunits. Neurochem Int 28: 445–452.
19. de Deyn P. Goeman J. Vervaet A. Dourcy-Belle-Rose B. van Dam D. Geerts E. (2011) Prevalence and incidence of dementia among 75–80-year-old community-dwelling elderly in different districts of Antwerp, Belgium: the Antwerp Cognition (ANCOG) Study. Clin Neurol Neurosurg 113: 736–745.
20. de Ronchi D. Berardi D. Menchetti M. Ferrari G. Serretti A. Dalmonte E. et al (2005) Occurrence of cognitive impairment and dementia after the age of 60: a population-based study from Northern Italy. Dement Geriatr Cogn Disord 19: 97–105.
21. Espey M. Chernyshev O. Reinhard J. Jr Namboodiri M. Colton C. (1997) Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 8: 431–434.
22. Fejes A. Pardutz A. Toldi J. Vécsei L. (2011) Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives. Curr Neuropharmacol 9: 376–387.
23. Feldman H. Jacova C. Robillard A. Garcia A. Chow T. Borrie M. et al (2008) Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ 178: 825–836.
24. Folstein M. Folstein S. McHugh P. (1975) ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198.
25. Forrest C. Mackay G. Oxford L. Millar K. Darlington L. Higgins M. et al (2011) Kynurenine metabolism predicts cognitive function in patients following cardiac bypass and thoracic surgery. J Neurochem 119: 136–152.
26. Foster A. White R. Schwarcz R. (1986) Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. J Neurochem 47: 23–30.
27. Fukui S. Schwarcz R. Rapoport S. Takada Y. Smith Q. (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56: 2007–2017.
28. Gandhi S. Abramov A. (2012) Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012: 428010.
29. Gauthier S. Patterson C. Chertkow H. Gordon M. Herrmann N. Rockwood K. et al. (2012) Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J 15: 120–126.
30. Gellert L. Varga D. Ruszka M. Toldi J. Farkas T. Szatmari I. et al (2012) Behavioural studies with a newly developed neuroprotective KYNA-amide. J Neural Transm 119: 165–172.
31. Gigler G. Szenasi G. Simo A. Levay G. Harsing L. Jr Sas K. et al (2007) Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol 564: 116–122.
32. Giorgini F. Guidetti P. Nguyen Q. Bennett S. Muchowski P. (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 37: 526–531.
33. Glass C. Saijo K. Winner B. Marchetto M. Gage F. (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918–934.
34. Gold A. Herrmann N. Swardfager W. Black S. Aviv R. Tennen G. et al (2011) The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment. J Neuroinflammation 8: 17.
35. Greenberg S. Rebeck G. Vonsattel J. Gomez-Isla T. Hyman B. (1995) Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 38: 254–259.
36. Guidetti P. Amori L. Sapko M. Okuno E. Schwarcz R. (2007) Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem 102: 103–111.
37. Guidetti P. Luthi-Carter R. Augood S. Schwarcz R. (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 17: 455–461.
38. Guillemin G. Brew B. (2002) Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep 7: 199–206.
39. Guillemin G. Brew B. Noonan C. Takikawa O. Cullen K. (2005 a) Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 31: 395–404.
40. Guillemin G. Kerr S. Brew B. (2005 b) Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res 7: 103–123.
41. Guillemin G. Kerr S. Smythe G. Smith D. Kapoor V. Armati P. et al (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78: 842–853.
42. Han Q. Cai T. Tagle D. Li J. (2010) Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci 67: 353–368.
43. Harris C. Miranda A. Tanguay J. Boegman R. Beninger R. Jhamandas K. (1998) Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br J Pharmacol 124: 391–399.
44. Hartai Z. Juhasz A. Rimanoczy A. Janaky T. Donko T. Dux L. et al (2007) Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem Int 50: 308–313.
45. Heyes M. Brew B. Martin A. Markey S. Price R. Bhalla R. et al (1991 a) Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Adv Exp Med Biol 294: 687–690.
46. Heyes M. Brew B. Martin A. Price R. Salazar A. Sidtis J. et al (1991 b) Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol 29: 202–209.
47. Heyes M. Saito K. Crowley J. Davis L. Demitrack M. Der M. et al (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115: 1249–1273.
48. Hilmas C. Pereira E. Alkondon M. Rassoulpour A. Schwarcz R. Albuquerque E. (2001) The brain metabolite kynurenic acid inhibits alpha 7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci 21: 7463–7473.
49. Honjo K. Black S. Verhoeff N. (2012) Alzheimer's disease, cerebrovascular disease, and the beta-amyloid cascade. Can J Neurol Sci 39: 712–728.
50. Hosaka A. Araki W. Oda A. Tomidokoro Y. Tamaoka A. (2013) Statins reduce amyloid beta-peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterol-independent mechanism in cultured neurons. Neurochem Res 38: 589–600.
51. Iadecola C. (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120: 287–296.
52. Iadecola C. Gorelick P. (2003) Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 34: 335–337.
53. Jauch D. Urbanska E. Guidetti P. Bird E. Vonsattel J. Whetsell W. Jr et al (1995) Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J Neurol Sci 130: 39–47.
54. Jeppsson F. Eketjall S. Janson J. Karlstrom S. Gustavsson S. Olsson L. et al (2012) Discovery of AZD3839, a potent and selective BACE 1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem 287: 41245–41257.
55. Kalbe E. Kessler J. Calabrese P. Smith R. Passmore A. Brand M. et al (2004) DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 19:136–143.
56. Karbowski M. Neutzner A. (2012) Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathol 123: 157–171.
57. Kaul M. Garden G. Lipton S. (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410: 988–994.
58. Kessler M. Terramani T. Lynch G. Baudry M. (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52: 1319–1328.
59. Knyihar-Csillik E. Mihaly A. Krisztin-Peva B. Robotka H. Szatmari I. Fulop F. et al (2008) The kynurenate analog SZR-72 prevents the nitroglycerol-induced increase of c-fos immunoreactivity in the rat caudal trigeminal nucleus: comparative studies of the effects of SZR-72 and kynurenic acid. Neurosci Res 61: 429–432.
60. Lapin I. (1978) Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. J Neural Transm 42: 37–43.
61. Lau A. Tymianski M. (2010) Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 460: 525–542.
62. Lehrmann E. Molinari A. Speciale C. Schwarcz R. (2001) Immunohistochemical visualization of newly formed quinolinate in the normal and excitotoxically lesioned rat striatum. Exp Brain Res 141: 389–397.
63. Liu H. Zhang J. (2012) Cerebral hypoperfusion and cognitive impairment: the pathogenic role of vascular oxidative stress. Int J Neurosci 122: 494–499.
64. Mahley R. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622–630.
65. Marzolo M. Bu G. (2009) Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. Semin Cell Dev Biol 20: 191–200.
66. Mejia-Arango S. Gutierrez L. (2011) Prevalence and incidence rates of dementia and cognitive impairment no dementia in the Mexican population: data from the Mexican Health and Aging Study. J Aging Health 23: 1050–1074.
67. Nasreddine Z. Phillips N. Bedirian V. Charbonneau S. Whitehead V. Collin I. et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53: 695–699.
68. Nestor P. Scheltens P. Hodges J. (2004) Advances in the early detection of Alzheimer's disease. Nat Med 10(Suppl.): S34–S41.
69. Ohno M. Sametsky E. Younkin L. Oakley H. Younkin S. Citron M. et al (2004) BACE 1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 41: 27–33.
70. Okuno E. Nakamura M. Schwarcz R. (1991) Two kynurenine aminotransferases in human brain. Brain Res 542: 307–312.
71. Oxenkrug G. (2007) Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann N Y Acad Sci 1122: 35–49.
72. Pardutz A. Fejes A. Bohar Z. Tar L. Toldi J. Vécsei L. (2012) Kynurenines and headache. J Neural Transm 119: 285–296.
73. Perkins M. Stone T. (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247: 184–187.
74. Plangar I. Zadori D. Klivenyi P. Toldi J. Vécsei L. (2011) Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy. J Alzheimers Dis 24(Suppl. 2): 199–209.
75. Potter M. Elmer G. Bergeron R. Albuquerque E. Guidetti P. Wu H. et al (2010) Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35: 1734–1742.
76. Potter P. (2010) Investigational medications for treatment of patients with Alzheimer disease. J Am Osteopath Assoc 110(9 Suppl. 8): S27–S36.
77. Rahman A. Ting K. Cullen K. Braidy N. Brew B. Guillemin G. (2009) The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PloS ONE 4: e6344.
78. Robotka H. Sas K. Agoston M. Rozsa E. Szenasi G. Gigler G. et al (2008) Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate. Life Sci 82: 915–919.
79. Rombouts S. Goekoop R. Stam C. Barkhof F. Scheltens P. (2005) Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. Neuroimage 26: 1078–1085.
80. Ruitenberg A. den Heijer T. Bakker S. van Swieten J. Koudstaal P. Hofman A. et al (2005) Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 57: 789–794.
81. Sapko M. Guidetti P. Yu P. Tagle D. Pellicciari R. Schwarcz R. (2006) Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp Neurol 197: 31–40.
82. Sas K. Robotka H. Rozsa E. Agoston M. Szenasi G. Gigler G. et al (2008) Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol Dis 32: 302–308.
83. Shulman K. (2000) Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15: 548–561.
84. Solomon P. Hirschoff A. Kelly B. Relin M. Brush M. de Veaux R. et al (1998) A 7 minute neurocognitive screening battery highly sensitive to Alzheimer's disease. Arch Neurol 55: 349–355.
85. Sorbi S. Hort J. Erkinjuntti T. Fladby T. Gainotti G. Gurvit H. et al (2012) EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 19: 1159–1179.
86. Stamford A. Scott J. Li S. Babu S. Tadesse D. Hunter R. et al (2012) Discovery of an orally available, brain penetrant BACE 1 inhibitor that affords robust CNS Aβ reduction. ACS Med Chem Lett 3: 897–902.
87. Stone T. Forrest C. Stoy N. Darlington L. (2012) Involvement of kynurenines in Huntington's disease and stroke-induced brain damage. J Neural Transm 119: 261–274.
88. Stone T. Perkins M. (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72: 411–412.
89. Stoy N. Mackay G. Forrest C. Christofides J. Egerton M. Stone T. et al (2005) Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 93: 611–623.
90. Szalardy L. Klivenyi P. Zadori D. Fulop F. Toldi J. Vécsei L. (2012) Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Curr Med Chem 19: 1899–1920.
91. Szekely C. Thorne J. Zandi P. Ek M. Messias E. Breitner J. et al (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23: 159–169.
92. Tajti J. Pardutz A. Vamos E. Tuka B. Kuris A. Bohar Z. et al (2011) Migraine is a neuronal disease. J Neural Transm 118: 511–524.
93. Tajti J. Szok D. Pardutz A. Tuka B. Csati A. Kuris A. et al (2012) Where does a migraine attack originate? In the brainstem. J Neural Transm 119: 557–568.
94. Tan L. Yu J. (2012) The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci 323: 1–8.
95. Tauber E. Miller-Fleming L. Mason R. Kwan W. Clapp J. Butler N. et al (2011) Functional gene expression profiling in yeast implicates translational dysfunction in mutant huntingtin toxicity. J Biol Chem 286: 410–419.
96. Thal D. Griffin W. de Vos R. Ghebremedhin E. (2008) Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol 115: 599–609.
97. Thal D. Grinberg L. Attems J. (2012) Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. Exp Gerontol 47: 816–824.
98. Valle M. Price R. Nilsson A. Heyes M. Verotta D. (2004) CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain 127: 1047–1060.
99. Vamos E. Fejes A. Koch J. Tajti J. Fulop F. Toldi J. et al (2010) Kynurenate derivative attenuates the nitroglycerin-induced CamKIIalpha and CGRP expression changes. Headache 50: 834–843.
100. Vassar R. (2004) BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 23: 105–114.
101. Vécsei L. (2005) Kynurenines in the Brain: From Experiments to Clinics. New York: Nova Biomedical Books.
102. Vécsei L. Beal M. (1990) Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats. Brain Res Bull 25: 623–627.
103. Vécsei L. Szalardy L. Fulop F. Toldi J. (2013) Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 12: 64–82.
104. Wang J. Simonavicius N. Wu X. Swaminath G. Reagan J. Tian H. et al (2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281: 22021–22028.
105. Weggen S. Eriksen J. Das P. Sagi S. Wang R. Pietrzik C. et al (2001) A subset of NSAIDs lower amyloidogenic Abeta 42 independently of cyclooxygenase activity. Nature 414: 212–216.
106. Widner B. Leblhuber F. Walli J. Tilz G. Demel U. Fuchs D. (2000) Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 107: 343–353.
107. Wolf H. (1974) The effect of hormones and vitamin B 6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest Suppl 136: 1–186.
108. Wolozin B. Kellman W. Ruosseau P. Celesia G. Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439–1443.
109. Yan Q. Zhang J. Liu H. Babu-Khan S. Vassar R. Biere A. et al (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23: 7504–7509.
110. Yu P. Li Z. Zhang L. Tagle D. Cai T. (2006) Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene 365: 111–118.
111. Zadori D. Klivenyi P. Plangar I. Toldi J. Vécsei L. (2011 a) Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med 15:701–717.
112. Zadori D. Nyiri G. Szonyi A. Szatmari I. Fulop F. Toldi J. et al (2011 b) Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. J Neural Transm 118: 865–875.
113. Zlokovic B. (2013) Cerebrovascular Effects of Apolipoprotein E: Implications for Alzheimer Disease. JAMA Neurol 70: 440–444.
114. Zwilling D. Huang S. Sathyasaikumar K. Notarangelo F. Guidetti P. Wu H. et al (2011) Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145: 863–874.